

Amendments to the Specification

Please amend the specification (based on the printed application) according to the following amendments.

[0014] The inventors have designed a drug-releasing nucleoside based on the mechanism of guanine decomposition by hole generation. The inventors examined a method of modifying the 8-position of guanine and found that basic site of the nucleotide which easily generates holes than natural ~~guaine~~ guanine, in other words, oxidizes easily, can be obtained by bonding a molecule to be released and guanine to each other via a heteroatom.

[0026] Then, the inventors examined long-range hole ~~transport~~ transport. Accordingly, they used an oligonucleotide containing tetramethylrhodamine (TAMRA)-^{eda}G, that is, 5'-(³²P)-d(ATTATAGTGTGGGTGTTXTTTATTAT)-3' (X represents a tetramethylrhodamine (TAMRA)-^{eda}G; hereinafter, this oligonucleotide is referred to as "ODN1"). As its complementary chains, the following chains were produced: 3'-d(TAAATATCACCCAACAACAAATAATA)-5' (hereinafter, this oligonucleotide is referred to as "ODN2(T)") and an oligonucleotide thereof wherein cyanobenzophenone-modified uridine as a hole injector was introduced in place of thymine (T) at the 7-position, that is, 3'-d(TAAATAU⁺CACCCAACAACAAATAATA)-5' (hereinafter, this oligonucleotide is referred to as "ODN2(U⁺)"). These oligonucleotides are shown in Fig. 4.

[0042] The compound represented by the general formula (I) in the present invention may be an oligonucleotide, and said oligonucleotide may contain[[ing]] the above-described modified guanine derivative having a molecular species to be released. Such oligonucleotide of the present invention has at least one modified guanine derivative having a molecular species to be released, and may have two or more modified guanine derivatives, if necessary. In this case, R¹ and R² in the formula (I) represent various nucleotides. Such nucleotide may have one or more bases.